By Dr Deepu
Patients with COPD and asthma have yet another medicinal option as Stiolto was approved in May 2015 by the U.S. Food and Drug Administration (US FDA). The medicine should now be available in pharmacies around the U.S. and few other countries.
The medicine is in the list of ever growing combination medicines approved for asthma and COPD.
Stiolto contains:
The medicine is in the list of ever growing combination medicines approved for asthma and COPD.
Stiolto contains:
- Tiotropium bromide (Spiriva), a long acting anticholinergic (LAAC)
- Olodaterol (Striverdi), a long acting beta adrenergic (LABA)
Studies showed Spiriva by itself improved lung function. another study has showed that Spiriva used in combination with Symbicort, a medicine that contains both a LABA and an inhaled corticosteroid, improves lung function by as much as 62 percent.
Before concluding I want to emphasise the fact that, approved medicine might benefit in people who are not relieved with other medicines. They are class of ultra long acting drugs so the dosage frequency is decreased which on a long run may decrease the treatment cost and also need for rescue medicines.
Time has to tell whether this medicine combination with satisfy the end user I.e the patient himself has to decide whether it works or not.
Before concluding I want to emphasise the fact that, approved medicine might benefit in people who are not relieved with other medicines. They are class of ultra long acting drugs so the dosage frequency is decreased which on a long run may decrease the treatment cost and also need for rescue medicines.
Further reading:
No comments:
Post a Comment
Please leave your comments